Jump to content
Scientific journal publication

Surface-Bioengineered Extracellular Vesicles Seeking Molecular Biotargets in Lung Cancer Cells

Kowalczyk, Agata; Dziubak, Damian; Kasprzak, Artur; Sobczak, Kamil; Ruzycka-Ayoush, Monika; Bamburowicz-Klimkows, Magdalena; Sęk, Sławomir; Rios-Mondragon, Ivan; Żołek, Teresa; Rundén-Pran, Elise; Shaposhnikov, Sergey; Cimpan, Mihaela Roxana; Dusinska, Maria; Grudzinski, Ireneusz P.; Nowicka, Anna M.

Publication details

Journal: ACS Applied Materials & Interfaces, 2024

Doi: doi.org/10.1021/acsami.4c04265

Personalized medicine is a new approach to modern oncology. Here, to facilitate the application of extracellular vesicles (EVs) derived from lung cancer cells as potent advanced therapy medicinal products in lung cancer, the EV membrane was functionalized with a specific ligand for targeting purposes. In this role, the most effective heptapeptide in binding to lung cancer cells (PTHTRWA) was used. The functionalization process of EV surface was performed through the C- or N-terminal end of the heptapeptide. To prove the activity of the EVs functionalized with PTHTRWA, both a model of lipid membrane mimicking normal and cancerous cell membranes as well as human adenocarcinomic alveolar basal epithelial cells (A549) and human normal bronchial epithelial cells (BEAS-2B) have been exposed to these bioconstructs. Magnetic resonance imaging (MRI) showed that the as-bioengineered PTHTRWA-EVs loaded with superparamagnetic iron oxide nanoparticle (SPIO) cargos reach the growing tumor when dosed intravenously in NUDE Balb/c mice bearing A549 cancer. Molecular dynamics (MD) in silico studies elucidated a high affinity of the synthesized peptide to the α5β1 integrin. Preclinical safety assays did not evidence any cytotoxic or genotoxic effects of the PTHTRWA-bioengineered EVs.